Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 291-295

  Horsley, Michael B ^a   Kahook, Malik Y ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Benzalkonium chloride; Glaucoma; Ocular surface; Prostaglandin analog

Indexed keywords

BENZALKONIUM CHLORIDE; DRUG PRESERVATIVE; LATANOPROST; OXIDIZING AGENT; SOFZIA; TRAVOPROST; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORNEA; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; OPEN STUDY; OUTCOME ASSESSMENT; SURFACE PROPERTY; TEAR FILM;

EID: 73949160909     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Wilcon LA. To preserve or not to preserve, is that the question? Br J Ophthalmol. 1996;80:583-584.
2. De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20:85-94.
3. Burstein NL. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol. 1980;25:15-30.
4. Burstein NL. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc UK. 1985;104:402-409.
5. De Jong C, Solwijk T, Kuppens E, et al. Topical timolol with and without benzalkonium chloride; epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994;232:221-224.
6. Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol. 1994;232:561-565.
7. Pisella PJ, Fillacier K, Elena P, et al. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res. 2000;32:3-8.
8. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205-215.
9. Baudouin C, de Lunardo C. Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998;82:39-42.
10. Norn MS, Opauszki A. Effects of ophthalmic vehicles on the stability of the precorneal tear film. Acta Ophthalmol. 1977;55:23-34.
11. Yalvaç IS, Gediko lu G, Karagöz Y, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995;73:246-248.
12. Kuppens EV, de Jong CA, Stolwijk TR, et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol. 1995;79:339-342.
13. Wilson WS, Duncan AJ, Jay JL. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol. 1975;59:667-669.
14. Herreras JM, Pastor JC, Calonge M, et al. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992;99:1082-1088.
15. Rolando M, Brezzo V, Giordano G, et al. In: van Bijsterveld OP, Lemp MA, Spinelli D, editors. Symposium on the lacrimal system. Singapore, March 1990. Amsterdam: Kugler and Ghedini; 1991. p. 87-91.
16. Holly FJ. Tear film formation and rupture: an update. In: Holly FJ, ed. The precorneal tear film in health diseases and contact lens wear. Dry Eye Institute Inc., Lubbock; 1986. p. 634-645.
17. Burstein NL. Preservative cytotoxic threshold for benzalkonium chloride and Chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci. 1980;19:308-313.
18. Marquardt R, Schubert T. Beeinflussung der Tränenfilmaufreisszeit (BUT) durch Betablocker-Augentropfen ohne Konservierungstoffe. Klin Monatsbl Augenheilkd. 1991;199:75-78.
19. Kahook M, Noecker R. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with SofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339-343.
20. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496.
21. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446-1454.
22. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006;23:511-519.
23. Schiffman RM, Christianson MD, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615-621.
24. Whitson JT, Cavanagh HD, Lakshman N, et al. Assessment of corneal epithelial integrity after exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006;23:663-671.
25. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98-103.